Stay updated on Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial
Sign up to get notified when there's something new on the Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial page.

Latest updates to the Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial page
- Check3 days agoChange DetectedA MedlinePlus genetics-related multiple myeloma reference was removed, and the site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check10 days agoChange DetectedThe clinical-trial page now presents the GMMG HD7 study record instead of a forbidden-access error. It describes the trial’s isatuximab treatment strategies for newly diagnosed multiple myeloma, along with study design, eligibility, outcomes, and participating locations.SummaryDifference90%

- Check17 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedA notice banner appears above the page, announcing NIH’s transition-related updates and use of “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check38 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check45 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 error.SummaryDifference0.2%

Stay in the know with updates to Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial page.